This “Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Cannabinoid Receptor Type 1 (CB1) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
CB1 antagonists work by binding to the CB1 receptors in the brain and peripheral tissues, preventing their activation by endogenous cannabinoids like anandamide or 2-arachidonoylglycerol. These receptors, part of the endocannabinoid system, play a pivotal role in regulating functions such as appetite, mood, memory, and pain sensation. By blocking CB1 receptor activation, antagonists can inhibit the downstream signaling pathways typically triggered by cannabinoid binding. This results in a reduction of effects like increased appetite and euphoria, making CB1 antagonists particularly useful in treating conditions like obesity, addiction, and metabolic disorders. At the molecular level, CB1 antagonists are non-competitive inhibitors, meaning they do not directly compete with the endogenous cannabinoids for the same binding site but instead bind to an alternative site that prevents receptor activation.
This allosteric binding mechanism results in a conformational change of the CB1 receptor that diminishes its ability to interact with G proteins, thus inhibiting the G-protein coupled signaling pathways typically initiated upon receptor activation. Additionally, these antagonists have the potential to influence other physiological processes, such as reducing neuroinflammation or modulating pain, which further broadens their therapeutic possibilities, though managing side effects and ensuring receptor selectivity remain key challenges in their development.
CB1 antagonists have significant therapeutic potential due to their ability to modulate the endocannabinoid system, which plays a central role in regulating numerous physiological processes. These compounds have been explored for a variety of conditions, most notably in the treatment of obesity and metabolic disorders, where they help to reduce appetite and promote weight loss by blocking the appetite-stimulating effects of CB1 activation. Additionally, CB1 antagonists are being investigated for their potential in managing substance use disorders, particularly in reducing cravings and withdrawal symptoms associated with addiction to alcohol, nicotine, and other substances.
“Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Cannabinoid Receptor Type 1 (CB1) Antagonist pipeline landscape is provided which includes the disease overview and Cannabinoid Receptor Type 1 (CB1) Antagonist treatment guidelines. The assessment part of the report embraces, in depth Cannabinoid Receptor Type 1 (CB1) Antagonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cannabinoid Receptor Type 1 (CB1) Antagonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This product will be delivered within 2 business days.
Cannabinoid Receptor Type 1 (CB1) Antagonist: Understanding
Cannabinoid Receptor Type 1 (CB1) Antagonist: Overview
Cannabinoid receptor 1 (CB1) antagonists are a class of compounds that block the activity of CB1 receptors, primarily found in the central nervous system and peripheral tissues. These receptors are part of the endocannabinoid system, which regulates various physiological processes such as appetite, mood, pain, and energy metabolism. By inhibiting CB1 receptor activation, these antagonists have shown potential in managing conditions like obesity, metabolic disorders, substance abuse, and neurodegenerative diseases.CB1 antagonists work by binding to the CB1 receptors in the brain and peripheral tissues, preventing their activation by endogenous cannabinoids like anandamide or 2-arachidonoylglycerol. These receptors, part of the endocannabinoid system, play a pivotal role in regulating functions such as appetite, mood, memory, and pain sensation. By blocking CB1 receptor activation, antagonists can inhibit the downstream signaling pathways typically triggered by cannabinoid binding. This results in a reduction of effects like increased appetite and euphoria, making CB1 antagonists particularly useful in treating conditions like obesity, addiction, and metabolic disorders. At the molecular level, CB1 antagonists are non-competitive inhibitors, meaning they do not directly compete with the endogenous cannabinoids for the same binding site but instead bind to an alternative site that prevents receptor activation.
This allosteric binding mechanism results in a conformational change of the CB1 receptor that diminishes its ability to interact with G proteins, thus inhibiting the G-protein coupled signaling pathways typically initiated upon receptor activation. Additionally, these antagonists have the potential to influence other physiological processes, such as reducing neuroinflammation or modulating pain, which further broadens their therapeutic possibilities, though managing side effects and ensuring receptor selectivity remain key challenges in their development.
CB1 antagonists have significant therapeutic potential due to their ability to modulate the endocannabinoid system, which plays a central role in regulating numerous physiological processes. These compounds have been explored for a variety of conditions, most notably in the treatment of obesity and metabolic disorders, where they help to reduce appetite and promote weight loss by blocking the appetite-stimulating effects of CB1 activation. Additionally, CB1 antagonists are being investigated for their potential in managing substance use disorders, particularly in reducing cravings and withdrawal symptoms associated with addiction to alcohol, nicotine, and other substances.
“Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Cannabinoid Receptor Type 1 (CB1) Antagonist pipeline landscape is provided which includes the disease overview and Cannabinoid Receptor Type 1 (CB1) Antagonist treatment guidelines. The assessment part of the report embraces, in depth Cannabinoid Receptor Type 1 (CB1) Antagonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cannabinoid Receptor Type 1 (CB1) Antagonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cannabinoid Receptor Type 1 (CB1) Antagonist R&D. The therapies under development are focused on novel approaches to treat/improve Cannabinoid Receptor Type 1 (CB1) Antagonist.Cannabinoid Receptor Type 1 (CB1) Antagonist Emerging Drugs Chapters
This segment of the Cannabinoid Receptor Type 1 (CB1) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Cannabinoid Receptor Type 1 (CB1) Antagonist Emerging Drugs
Nimacimab: Skye Biologics Holdings
Nimacimab is a first-in-class humanized monoclonal antibody that acts as a negative allosteric modulator to inhibit CB1 signaling in the periphery. It functions as a negative allosteric modulator targeting the cannabinoid 1 receptor (CB1), specifically inhibiting its signaling in peripheral tissues. This mechanism has shown promise in addressing various conditions, particularly obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH), due to its anti-fibrotic, anti-inflammatory, and metabolic effects. Currently, the drug is in the Phase II stage of its development for the treatment of Obesity.Cannabinoid Receptor Type 1 (CB1) Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Cannabinoid Receptor Type 1 (CB1) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Cannabinoid Receptor Type 1 (CB1) Antagonist
There are approx. 4+ key companies which are developing the therapies for Cannabinoid Receptor Type 1 (CB1) Antagonist. The companies which have their Cannabinoid Receptor Type 1 (CB1) Antagonist drug candidates in the most advanced stage, i.e. Phase II include, Skye Biologics Holdings.Phases
The report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Cannabinoid Receptor Type 1 (CB1) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Cannabinoid Receptor Type 1 (CB1) Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cannabinoid Receptor Type 1 (CB1) Antagonist therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cannabinoid Receptor Type 1 (CB1) Antagonist drugs.Cannabinoid Receptor Type 1 (CB1) Antagonist Report Insights
- Cannabinoid Receptor Type 1 (CB1) Antagonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cannabinoid Receptor Type 1 (CB1) Antagonist Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cannabinoid Receptor Type 1 (CB1) Antagonist drugs?
- How many Cannabinoid Receptor Type 1 (CB1) Antagonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cannabinoid Receptor Type 1 (CB1) Antagonist?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cannabinoid Receptor Type 1 (CB1) Antagonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cannabinoid Receptor Type 1 (CB1) Antagonist and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Skye Biologics Holdings
- Aelis Farma
Key Products
- Nimacimab
- AEF0217
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryCannabinoid Receptor Type 1 (CB1) Antagonist - The Publisher's Analytical PerspectiveMid Stage Products (Phase II)Cannabinoid Receptor Type 1 (CB1) Antagonist - Collaborations Assessment- Licensing/Partnering/FundingCannabinoid Receptor Type 1 (CB1) Antagonist - Unmet NeedsCannabinoid Receptor Type 1 (CB1) Antagonist - Market Drivers and BarriersAppendix
Cannabinoid Receptor Type 1 (CB1) Antagonist: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Drug Name: Company Name
Mid Stage Products (Phase II)
Nimacimab: Skye Biologics Holdings
Early Stage Products (Phase I)
Drug Name: Company Name
Preclinical Stage Products
Drug Name: Company Name
Inactive Products
List of Table
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Skye Biologics Holdings
- Aelis Farma
